STOCK TITAN

Amarin Corp Plc - $AMRN STOCK NEWS

Welcome to our dedicated page for Amarin Plc news (Ticker: $AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amarin Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amarin Plc's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
covid-19
Amarin Corp Plc

Nasdaq:AMRN

AMRN Rankings

AMRN Stock Data

402.65M
383.11M
1.54%
23.81%
4.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 2

About AMRN

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.